576 related articles for article (PubMed ID: 23690483)
21. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.
Besser MJ; Treves AJ; Itzhaki O; Hardan I; Nagler A; Papa MZ; Catane R; Winkler E; Shalmon-Zifroni B; Schachter J
Isr Med Assoc J; 2006 Mar; 8(3):164-8. PubMed ID: 16599050
[TBL] [Abstract][Full Text] [Related]
22. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
23. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
[TBL] [Abstract][Full Text] [Related]
24. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
[TBL] [Abstract][Full Text] [Related]
25. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
Arienti F; Belli F; Rivoltini L; Gambacorti-Passerini C; Furlan L; Mascheroni L; Prada A; Rizzi M; Marchesi E; Vaglini M
Cancer Immunol Immunother; 1993 May; 36(5):315-22. PubMed ID: 8477417
[TBL] [Abstract][Full Text] [Related]
27. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
[TBL] [Abstract][Full Text] [Related]
28. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
29. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
30. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
31. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
[TBL] [Abstract][Full Text] [Related]
33. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Rosenberg SA; Yang JC; Sherry RM; Kammula US; Hughes MS; Phan GQ; Citrin DE; Restifo NP; Robbins PF; Wunderlich JR; Morton KE; Laurencot CM; Steinberg SM; White DE; Dudley ME
Clin Cancer Res; 2011 Jul; 17(13):4550-7. PubMed ID: 21498393
[TBL] [Abstract][Full Text] [Related]
34. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.
Saint-Jean M; Knol AC; Volteau C; Quéreux G; Peuvrel L; Brocard A; Pandolfino MC; Saiagh S; Nguyen JM; Bedane C; Basset-Seguin N; Khammari A; Dréno B
J Immunol Res; 2018; 2018():3530148. PubMed ID: 29750176
[TBL] [Abstract][Full Text] [Related]
35. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
Goff SL; Dudley ME; Citrin DE; Somerville RP; Wunderlich JR; Danforth DN; Zlott DA; Yang JC; Sherry RM; Kammula US; Klebanoff CA; Hughes MS; Restifo NP; Langhan MM; Shelton TE; Lu L; Kwong ML; Ilyas S; Klemen ND; Payabyab EC; Morton KE; Toomey MA; Steinberg SM; White DE; Rosenberg SA
J Clin Oncol; 2016 Jul; 34(20):2389-97. PubMed ID: 27217459
[TBL] [Abstract][Full Text] [Related]
36. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial.
Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B
Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
[TBL] [Abstract][Full Text] [Related]
38. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
39. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Dudley ME; Wunderlich JR; Yang JC; Sherry RM; Topalian SL; Restifo NP; Royal RE; Kammula U; White DE; Mavroukakis SA; Rogers LJ; Gracia GJ; Jones SA; Mangiameli DP; Pelletier MM; Gea-Banacloche J; Robinson MR; Berman DM; Filie AC; Abati A; Rosenberg SA
J Clin Oncol; 2005 Apr; 23(10):2346-57. PubMed ID: 15800326
[TBL] [Abstract][Full Text] [Related]
40. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]